Pathophysiology: Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium responsible for several difficult-to-treat infections in humans. Healthy individuals may carry MRSA asymptomatically for periods ranging from a few weeks to many years. Patients with compromised immune systems are at a significantly greater risk of symptomatic secondary infection. Initial treatment of the infection is often based upon 'strong suspicion' and techniques by the treating physician; these include quantitative PCR procedures.
Statistics: The total number of SA infection was 58 cases, these the incidence of SA-infections was 3.3% and 1.0/1,000 pds. The incidence of MRSA infections (19 cases) was 1.1%. No significant association was found between time of hospitalization in NICU and the risk of MRSA. The number of MRSA infections in the group of SAinfections proportion was 32.8 (range from 8.3% to 42.1% in different centers). The most common SAinfections were BSI (55.2%) and pneumonia (39.7%).
Treatment: Treatment for MRSA will depends up on the how prevalence it is and also on the type of the infection caused. Mostly Treatment options for MRSA skin and soft tissue infections may include ClindamycinTetracycline drugs, Doxycycline and Minocycline,Trimethoprim andSulfamethoxazole, Rifampin and Linezolid.
An entirely different approach is phage therapy (e.g., at the Eliava Institute in Georgia). Experimental phage therapy tested in mice had a reported efficacy against up to 95% of tested Staphylococcus isolates.Some semi-toxic fungi/mushrooms excrete broad spectrum antibiotics, not all of which have been fully identified; some have been shown to inhibit the growth of Staphylococcus aureus.